Filing Analysis
Regulation FD Disclosure
Filed Mar 20, 2026
LOW
Milestone Pharmaceuticals Inc. announced its fourth quarter and full-year 2025 financial results and provided a commercial update on its lead product, CARDAMYST™ (etripamil) Nasal Spray.
Key Facts
- Financial results reported for the fiscal year and quarter ended December 31, 2025.
- Provided a commercial launch update for CARDAMYST™ (etripamil) Nasal Spray for the treatment of Paroxysmal Supraventricular Tachycardia (PSVT).
- The filing was made under Item 2.02 (Results of Operations and Financial Condition).
- Amit Hasija, Chief Financial Officer, signed the report on March 20, 2026.
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.